Related references
Note: Only part of the references are listed.Pharmacodynamic study of nimotuzumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb), in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN): A SENDO Foundation study
F. Rojo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Preliminary results of an escalating dose phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy
D. G. Bebb et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Current situation of zalutumumab
Fernando Rivera et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Prophylactic Intravenous Immunoglobulin Does Not Have a Role in Hematopoietic Stem-Cell Transplantation: Is the Evidence Clear?
Nishitha Reddy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
FDA Review of a Panitumumab (Vectibix (TM)) Clinical Trial for First-Line Treatment of Metastatic Colorectal Cancer
Ruthann M. Giusti et al.
ONCOLOGIST (2009)
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: A single institution retrospective analysis
Michele Orditura et al.
ONCOLOGY REPORTS (2009)
Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab
Fernando Rivera et al.
ACTA ONCOLOGICA (2008)
Cetuximab, its clinical use and future perspectives
Fernando Rivera et al.
ANTI-CANCER DRUGS (2008)
Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
Y. Akashi et al.
BRITISH JOURNAL OF CANCER (2008)
Palliative thoracic radiotherapy for lung cancer: A systematic review
Alysa Fairchild et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Requirement of hypoxia-inducible factor-1α down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab
Xinqun Li et al.
MOLECULAR CANCER THERAPEUTICS (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities
Arlhee Diaz Miqueli et al.
HYBRIDOMA (2007)
Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials
J. Berlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
EGFR-targeted anti-cancer drugs in radiotherapy:: Preclinical evaluation of mechanisms
Michael Baumann et al.
RADIOTHERAPY AND ONCOLOGY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study
Sabine Tejpar et al.
LANCET ONCOLOGY (2007)
Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management
Jenny C. Hu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Phase I clinical study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody (Nimotuzumab) in combination with chemotherapy in patients with locally-advanced breast cancer. Preliminary results
J. Soriano et al.
EJC SUPPLEMENTS (2007)
BIOMAb EGFRTM (Nimotuzumab/h-r3) in combination with standard of care in squamous cell carcinoma of head and neck (SCCHN)
B. K. Reddy et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors
Anna Liza C. Agero et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
SQ Li et al.
CANCER CELL (2005)
Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
T Crombet et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Signaling through the epidermal growth factor receptor during the development of malignancy
JR Grandis et al.
PHARMACOLOGY & THERAPEUTICS (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer
T Crombet et al.
JOURNAL OF IMMUNOTHERAPY (2003)
Antiproliferative, antiangiogenic and proapoptotic activity of h-R3:: A humanized anti-EGFR antibody
T Crombet-Ramos et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase
ZM Lu et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Tumor invasion as dysregulated cell motility
J Kassis et al.
SEMINARS IN CANCER BIOLOGY (2001)
Share Paper
